Annual CFF
$7.53 M
-$3.02 M-28.60%
December 31, 2023
Summary
- As of February 7, 2025, ATXI annual cash flow from financing activities is $7.53 million, with the most recent change of -$3.02 million (-28.60%) on December 31, 2023.
- During the last 3 years, ATXI annual CFF has risen by +$7.53 million (+100.00%).
- ATXI annual CFF is now -76.72% below its all-time high of $32.33 million, reached on December 31, 2019.
Performance
ATXI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$567.00 K
-$3.41 M-85.75%
September 30, 2024
Summary
- As of February 7, 2025, ATXI quarterly cash flow from financing activities is $567.00 thousand, with the most recent change of -$3.41 million (-85.75%) on September 30, 2024.
- Over the past year, ATXI quarterly CFF has dropped by -$3.38 million (-85.63%).
- ATXI quarterly CFF is now -98.39% below its all-time high of $35.30 million, reached on June 30, 2017.
Performance
ATXI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$13.02 M
+$88.00 K+0.68%
September 30, 2024
Summary
- As of February 7, 2025, ATXI TTM cash flow from financing activities is $13.02 million, with the most recent change of +$88.00 thousand (+0.68%) on September 30, 2024.
- Over the past year, ATXI TTM CFF has increased by +$5.50 million (+73.03%).
- ATXI TTM CFF is now -63.65% below its all-time high of $35.82 million, reached on June 30, 2017.
Performance
ATXI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ATXI Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.6% | -85.6% | +73.0% |
| 3 y3 years | +100.0% | -87.1% | +197.2% |
| 5 y5 years | +940.9% | +100.0% | - |
ATXI Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -28.6% | +71.8% | -94.7% | +576.5% | -8.6% | +205.5% |
| 5 y | 5-year | -76.7% | -100.0% | -94.7% | +576.5% | -59.7% | -100.0% |
| alltime | all time | -76.7% | +940.9% | -98.4% | +108.4% | -63.6% | +292.8% |
Avenue Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $567.00 K(-85.7%) | $13.02 M(+0.7%) |
| Jun 2024 | - | $3.98 M(-12.2%) | $12.93 M(+44.4%) |
| Mar 2024 | - | $4.53 M(+14.8%) | $8.96 M(+19.0%) |
| Dec 2023 | $7.53 M(-28.6%) | $3.95 M(+723.8%) | $7.53 M(-47.1%) |
| Sep 2023 | - | $479.00 K(>+9900.0%) | $14.24 M(+4.4%) |
| Jun 2023 | - | $0.00(-100.0%) | $13.64 M(0.0%) |
| Mar 2023 | - | $3.10 M(-70.9%) | $13.64 M(+29.4%) |
| Dec 2022 | $10.54 M(+140.6%) | $10.66 M(-9058.0%) | $10.54 M(+147.3%) |
| Sep 2022 | - | -$119.00 K(<-9900.0%) | $4.26 M(-2.7%) |
| Jun 2022 | - | $0.00(0.0%) | $4.38 M(0.0%) |
| Mar 2022 | - | $0.00(-100.0%) | $4.38 M(0.0%) |
| Dec 2021 | $4.38 M(>+9900.0%) | $4.38 M(>+9900.0%) | $4.38 M(>+9900.0%) |
| Sep 2021 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2020 | $0.00(-100.0%) | - | - |
| Dec 2019 | $32.33 M | $0.00(0.0%) | $32.33 M(+2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | $0.00(-100.0%) | $31.44 M(0.0%) |
| Jun 2019 | - | -$12.00 K(-100.0%) | $31.44 M(-0.0%) |
| Mar 2019 | - | $32.34 M(-3714.0%) | $31.45 M(-3614.0%) |
| Dec 2018 | -$895.00 K(-103.2%) | -$895.00 K(<-9900.0%) | -$895.00 K(<-9900.0%) |
| Sep 2018 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Jun 2018 | - | $0.00(0.0%) | -$6.75 M(-123.7%) |
| Mar 2018 | - | $0.00(0.0%) | $28.55 M(+0.6%) |
| Dec 2017 | $28.39 M(+1464.0%) | $0.00(-100.0%) | $28.39 M(-0.8%) |
| Sep 2017 | - | -$6.75 M(-119.1%) | $28.63 M(-20.1%) |
| Jun 2017 | - | $35.30 M(<-9900.0%) | $35.82 M(+4510.3%) |
| Mar 2017 | - | -$163.00 K(-167.9%) | $777.00 K(-57.2%) |
| Dec 2016 | $1.81 M | $240.00 K(-45.6%) | $1.81 M(+15.2%) |
| Sep 2016 | - | $441.00 K(+70.3%) | $1.57 M(+38.9%) |
| Jun 2016 | - | $259.00 K(-70.4%) | $1.13 M(+29.6%) |
| Mar 2016 | - | $875.00 K | $875.00 K |
FAQ
- What is Avenue Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Avenue Therapeutics?
- What is Avenue Therapeutics annual CFF year-on-year change?
- What is Avenue Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Avenue Therapeutics?
- What is Avenue Therapeutics quarterly CFF year-on-year change?
- What is Avenue Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Avenue Therapeutics?
- What is Avenue Therapeutics TTM CFF year-on-year change?
What is Avenue Therapeutics annual cash flow from financing activities?
The current annual CFF of ATXI is $7.53 M
What is the all time high annual CFF for Avenue Therapeutics?
Avenue Therapeutics all-time high annual cash flow from financing activities is $32.33 M
What is Avenue Therapeutics annual CFF year-on-year change?
Over the past year, ATXI annual cash flow from financing activities has changed by -$3.02 M (-28.60%)
What is Avenue Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ATXI is $567.00 K
What is the all time high quarterly CFF for Avenue Therapeutics?
Avenue Therapeutics all-time high quarterly cash flow from financing activities is $35.30 M
What is Avenue Therapeutics quarterly CFF year-on-year change?
Over the past year, ATXI quarterly cash flow from financing activities has changed by -$3.38 M (-85.63%)
What is Avenue Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ATXI is $13.02 M
What is the all time high TTM CFF for Avenue Therapeutics?
Avenue Therapeutics all-time high TTM cash flow from financing activities is $35.82 M
What is Avenue Therapeutics TTM CFF year-on-year change?
Over the past year, ATXI TTM cash flow from financing activities has changed by +$5.50 M (+73.03%)